HARRISBURG, PA — Attorney General Dave Sunday has issued a warning to Pennsylvanians about the risks of counterfeit GLP-1 receptor agonist drugs, which are widely used for managing diabetes and weight loss. Rising demand for these medications, including brand names like Mounjaro, Zepbound, Ozempic, and Wegovy, has outpaced supply, creating a market for counterfeit versions, often originating from overseas.
“These counterfeit products flooding the market can cause harm, and I strongly advise anyone shopping for GLP-1 drugs to use extreme caution,” Attorney General Sunday stated. He highlighted the dangers associated with unlicensed or fake medications and urged residents to only purchase these drugs from legitimate, licensed pharmacies.
The Attorney General also called on the Food and Drug Administration (FDA) to take stronger action against those pushing counterfeit drugs. Joining a coalition of state attorneys general, Sunday sent a letter to the FDA urging it to ramp up efforts using its “investigative, inspection, and enforcement powers to protect consumers.”
The unprecedented popularity of GLP-1 drugs for both diabetes treatment and weight loss has created an environment ripe for exploitation. Supply shortages and elevated costs have left consumers vulnerable to fraudulent products marketed as affordable alternatives.
Pennsylvanians are encouraged to report any suspicions of counterfeit medications to the FDA or the Office of the Attorney General. Sunday’s advice is clear as the summer season approaches and people focus on their health goals. “Prioritize your health,” he urged, “over efforts to lose a few more pounds.”
Consumers should remain vigilant and prioritize their safety by ensuring the authenticity of their medications.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.